Assembly Bio raises $12.6M via equity sales to Armistice & Gilead; cash runway into Q1 2026

ASSEMBLY BIOSCIENCES, INC.

Gross proceeds of $12.6M from sale of common stock and warrants to Armistice Capital and Gilead.
Armistice bought 634,500 shares + warrants; Gilead bought 179,500 shares + warrants at $15.46/combined unit.
Warrants exercisable at $17.00/share, expire June 18, 2029; proceeds for general corporate purposes.
Cash runway extended into Q1 2026; key data readouts: ABI-5366 Phase 1a in Q3 2024, Phase 1b in H1 2025.
Agreement amendments with Gilead extend timeline for potential ownership increase up to 29.9%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.